BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 15200450)

  • 21. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
    Wang J; Zhu N; Yuan W
    Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats.
    Połubinska A; Pawlaczyk K; Kuzlan-Pawlaczyk M; Wieczorowska-Tobis K; Chen C; Moberly JB; Martis L; Breborowicz A; Oreopoulos DG
    Kidney Int; 2000 Mar; 57(3):1182-9. PubMed ID: 10720971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor in peritoneal dialysis patients.
    Jovanović N; Božinovski SŽ; Krstić S; Obrenović R; Trbojević-Stanković J; Stojimirović B
    Clin Lab; 2014; 60(10):1695-701. PubMed ID: 25651716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions.
    Cooker LA; Luneburg P; Holmes CJ; Jones S; Topley N;
    Perit Dial Int; 2001; 21 Suppl 3():S102-7. PubMed ID: 11887802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of intraperitoneal hyaluronan on peritoneal fluid and solute transport in peritoneal dialysis patients.
    Moberly JB; Sorkin M; Kucharski A; Ogle K; Mongoven J; Skoufos L; Lin L; Bailey S; Rodela H; Mupas L; Walele A; Ogrinc F; White D; Wolfson M; Martis L; Breborowicz A; Oreopoulos DG
    Perit Dial Int; 2003; 23(1):63-73. PubMed ID: 12691509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children.
    Schmitt CP; Haraldsson B; Doetschmann R; Zimmering M; Greiner C; Böswald M; Klaus G; Passlick-Deetjen J; Schaefer F
    Kidney Int; 2002 Apr; 61(4):1527-36. PubMed ID: 11918761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
    Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.
    Yohanna S; Alkatheeri AM; Brimble SK; McCormick B; Iansavitchous A; Blake PG; Jain AK
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1380-8. PubMed ID: 26048890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
    Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
    Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
    Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
    Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.
    Haas S; Schmitt CP; Arbeiter K; Bonzel KE; Fischbach M; John U; Pieper AK; Schaub TP; Passlick-Deetjen J; Mehls O; Schaefer F
    J Am Soc Nephrol; 2003 Oct; 14(10):2632-8. PubMed ID: 14514742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
    Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
    Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture.
    Simonsen O; Sterner G; Carlsson O; Wieslander A; Rippe B
    Perit Dial Int; 2006; 26(3):353-9. PubMed ID: 16722029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
    Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
    Perl J; Nessim SJ; Bargman JM
    Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of low-GDP bicarbonate-lactate-buffered peritoneal dialysis solutions on plasma levels of adipokines and gut appetite-regulatory peptides. A randomized crossover study.
    Rodríguez-Carmona A; Pérez-Fontán M; Guitián A; Peteiro J; García-Falcón T; López-Muñiz A; García-Buela J; Cordido F
    Nephrol Dial Transplant; 2012 Jan; 27(1):369-74. PubMed ID: 21562143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions.
    Pajek J; Kveder R; Gucek A; Skoberne A; Bren A; Bucar M; Cerne D; Lukac-Bajalo J
    Ther Apher Dial; 2010 Feb; 14(1):20-6. PubMed ID: 20438516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.